Literature DB >> 30465494

Progresses in microRNA Delivery Using Synthetic Nanovectors in Cancer Therapy.

Sanaz Javanmardi1, Mahmoud Reza Aghamaali1, Samira Sadat Abolmaali2, Ali Mohammad Tamaddon3.   

Abstract

MicroRNAs are small noncoding RNAs with key roles in gene expression. It has been revealed that aberrant expression of microRNAs is related to gene expression abnormality, and they have the potential to be used as anti-cancer drugs. However, the delivery of microRNAs is limited due to barriers, such as low uptake and insufficient endosomal release, intracellular nucleases degradation, phagocytic elimination, and renal filtration. To overcome these issues, novel delivery systems are developed for improving the efficiency of microRNAs therapy ranging from viral to synthetic; some are further developed with targeted ligands for active targeting purposes. Such delivery systems provide efficient cellular uptake and endosomal release as well as low cytotoxicity and minimum unwanted host immune response. Nevertheless, more complementary studies are warranted before being applied in human studies. This review deals with recent updates on the challenges and achievements of the various nanotechnology-based gene delivery vehicles with a special emphasis on the miRNA delivery in cancer therapy. In addition, we attempted to categorize the designed delivery systems based on miRNA therapeutic molecule. The related cellular signaling pathways and pharmacological action against cancer promotion have also been highlighted. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  cancer therapy; combination therapy; delivery system; gene expression; microRNA; renal filtration.

Mesh:

Substances:

Year:  2018        PMID: 30465494     DOI: 10.2174/1381612825666181120160316

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  2 in total

Review 1.  Pancreatic Ductal Adenocarcinoma: MicroRNAs Affecting Tumor Growth and Metastasis in Preclinical In Vivo Models.

Authors:  Ulrich H Weidle; Fabian Birzele; Adam Nopora
Journal:  Cancer Genomics Proteomics       Date:  2019 Nov-Dec       Impact factor: 4.069

2.  LncRNA NEAT1 Interacted With DNMT1 to Regulate Malignant Phenotype of Cancer Cell and Cytotoxic T Cell Infiltration via Epigenetic Inhibition of p53, cGAS, and STING in Lung Cancer.

Authors:  Fang Ma; Yi-Yu Lei; Meng-Ge Ding; Li-Hua Luo; Yang-Chun Xie; Xian-Ling Liu
Journal:  Front Genet       Date:  2020-03-31       Impact factor: 4.599

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.